Status:
COMPLETED
Detecting Transitional Cell Carcinoma From Haematuria
Lead Sponsor:
Hull University Teaching Hospitals NHS Trust
Collaborating Sponsors:
C-Term Diagnostics Ltd
Hull York Medical School
Conditions:
Transitional Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
To validate ELISAs for the detection of urinary tissue factor (TF) in patients suspected of having bladder cancer.
Detailed Description
The effective diagnosis of transitional cell carcinoma (TCC), the most common form of bladder cancer, is often quite challenging, due to a lack of disease-specific symptoms. Detecting TCC early is cru...
Eligibility Criteria
Inclusion
- Capable of giving written informed consent
- Age ≥18 years
- Referral to haematuria clinic (gross or microscopic haematuria)
Exclusion
- Inability to provide written informed consent
- Previous radiotherapy to the bladder (e.g. prostate cancer)
- Active urinary tract infection (Patients may be re-approached at later opportunity when urinary infection is cleared and haematuria persists)
- Current or planned treatment with neoadjuvant chemotherapy or radiotherapy
- Other known malignant condition, either active or in complete remission ≤5 years
- HIV, hepatitis C, or any other known communicable disease
Key Trial Info
Start Date :
October 18 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 16 2019
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT03256877
Start Date
October 18 2016
End Date
May 16 2019
Last Update
July 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Castle Hill Hospital
Hull, United Kingdom, HU16 5JQ